MIM
SPRY icon

Monashee Investment Management’s ARS Pharmaceuticals SPRY Stock Holding History

Monashee Investment Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-60,000
Closed -$2.78M – 429
2020
Q4 		$2.78M Buy
+60,000
New +$2M 0.37% 70

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Monashee Investment Management's SPRY Position: Q1 2021 in Review

Monashee Investment Management sold out of ARS Pharmaceuticals (SPRY) in Q1 2021, closing a stake of 60,000 shares — an estimated $2.78M sold.

Monashee Investment Management first reported a position in SPRY in Q4 2020 and held it in 1 quarter. The position peaked at $2.78M in Q4 2020. 68 funds tracked by Wall St. Rank hold SPRY as of Q1 2021.

  • Monashee Investment Management reported no remaining ARS Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Monashee Investment Management sold 60,000 ARS Pharmaceuticals shares in Q1 2021, an estimated $2.78M.
  • Monashee Investment Management first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Monashee Investment Management's ARS Pharmaceuticals position peaked at $2.78M in Q4 2020.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2021.

Based on Monashee Investment Management's 13F filing for Q1 2021, filed 14 May 2021.